NCT05350787

To Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Relapsed and Refractory Acute B-cell Leukemia

Study Summary

This is an open label, phase I study to assess the safety, efficacy and pharmacokinetics of ThisCART19A in patients with relapsed and refractory acute B-cell leukemia

Want to learn more about this trial?

Request More Info

Interventions

ThisCART19ABIOLOGICAL
ThisCART19A is a new type CAR-T cells therapy for patients with acute B-cell leukemia

Study Locations

FacilityCityStateCountry
The First Hospital of Zhejiang Medical Colleage Zhejiang UniversityHangzhouZhejiangChina
The first affiliated hospital of medical college of zhejiang universityHangzhouZhejiangChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026